News

SAN DIEGO – November 16, 2016 – Amplyx Pharmaceuticals, a company developing novel antifungal agents for life-threatening fungal infections, announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Product Development has granted orphan drug designation to APX001, the company’s lead drug candidate.

Long-term collaboration for US distribution of Tryton Side Branch Stent pending regulatory approval. DURHAM, NC – October 27, 2016 – Tryton Medical, Inc., the leading developer of stents designed to treat coronary bifurcation lesions, and Cardinal Health, a global integrated healthcare services and products company, today announced that the companies have established a long-term strategic […]

Preclinical Data from Multiple Models of Fibrosis and Collagen Deposition Presented at 1st International Conference on Tissue Repair, Regeneration, and Fibrosis SAN CARLOS, Calif., September 26, 2016 – New preclinical research presented by Allakos, Inc., shows the potential of the company’s recombinant antibodies to Siglec-8, an inhibitory receptor selectively expressed on the immune system’s mast […]

Cleveland, OH, September. 15, 2016 — Securus Medical Group, Inc., a privately held medical device company, announced the closing of a $10 million Series C financing led by Boston Scientific Corporation. Boston Scientific joined with existing investors RiverVest Venture Partners, 3X5 Special Opportunity Fund, and the University of Michigan MINTS program, as well as another […]

SAN DIEGO, Sept. 12, 2016 /PRNewswire/ — Amplyx Pharmaceuticals today announced the initiation of dosing in a Phase 1 clinical trial of APX001 in healthy volunteers. The randomized, double-blind, placebo-controlled, dose-escalation study will enroll approximately 80 healthy subjects. Intravenous infusion of APX001 will be administered as a single or multiple consecutive doses to healthy subjects. […]

SAN CARLOS, Calif., Sept. 8, 2016 – Allakos, Inc., today announced it has initiated a Phase 2 clinical trial of AK001, its lead therapeutic antibody, in patients with nasal polyposis with and without asthma. This multicenter trial with sites in the U.S. and Europe will evaluate the activity of two dose levels of AK001 compared […]

Funding Includes Support of Clinical Development of Anti-CD47 Antibody Program in Multiple Cancer Immunotherapy Trials Executive Team Headed by Biotech Industry Veteran John Donovan ST. LOUIS, MO and BRISBANE, CA–(Marketwired – Aug 16, 2016) – Tioma Therapeutics, Inc., a venture-stage biopharmaceutical company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers, today announced […]

SAN DIEGO, Aug. 01, 2016 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced the successful completion of a one-year, multiple-dose clinical safety trial of OTO-104 in patients with Ménière’s disease.

SAN DIEGO, June 09, 2016 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced the enrollment of the first patient in the single OTIPRIOTM Phase 3 clinical trial in pediatric and adult patients with acute otitis externa […]

SAN DIEGO, May 16, 2016 (GLOBE NEWSWIRE) — Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced the upcoming presentation of results from an OTIPRIO™ (ciprofloxacin otic suspension) Phase 3b trial